<DOC>
	<DOCNO>NCT00075673</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy , vinorelbine , work different way stop tumor cell divide stop grow die . Combining vinorelbine celecoxib may kill tumor cell . PURPOSE : Phase I trial determine effectiveness combine vinorelbine celecoxib treat woman relapse metastatic breast cancer .</brief_summary>
	<brief_title>Vinorelbine Celecoxib Treating Women With Relapsed Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose vinorelbine celecoxib woman relapse metastatic breast cancer . - Determine safety profile regimen patient . OUTLINE : This dose-escalation study . Patients receive oral celecoxib twice daily day 1-21 oral vinorelbine day 7 , 14 , 21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos celecoxib vinorelbine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 12-18 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Recurrent metastatic ( stage IV ) disease Incurable disease Measurable evaluable disease Stable brain metastasis allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Hepatic Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min No clinically significant proteinuria No impair renal function Cardiovascular No symptomatic congestive heart failure No unstable angina No cardiac arrhythmia No inadequately control hypertension Gastrointestinal No disorder would alter gastrointestinal motility absorption No dysphagia Able swallow tablet capsule Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No hypersensitivity celecoxib No prior urticaria , asthma , allergictype reaction take aspirin nonsteroidal antiinflammatory drug No allergy sulfa No concurrent uncontrolled illness No psychiatric illness social situation would preclude study compliance No ongoing active infection PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 week since prior trastuzumab ( Herceptin® ) recover No concurrent hematopoietic growth factor Chemotherapy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior adjuvant neoadjuvant chemotherapy allow Prior chemotherapy recurrent metastatic disease allow No prior vinorelbine Endocrine therapy At least 2 week since prior hormonal therapy Prior adjuvant neoadjuvant hormonal therapy allow Prior hormonal therapy recurrent metastatic disease allow Radiotherapy At least 4 week since prior radiotherapy metastatic disease Prior adjuvant radiotherapy allow Surgery Not specify Other At least 3 week since prior investigational anticancer agent recover At least 1 week since prior cyclooxygenase2 ( COX2 ) inhibitor , except celecoxib No concurrent administration follow drug : Lithium Fluconazole Aluminum antacid Magnesium antacid Concurrent H_2 block agent proton pump inhibitor allow treatment dyspepsia gastroesophageal reflux disease Concurrent bisphosphonates allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>